Literature DB >> 18239619

Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation.

R Jamal, C Bélisle, M-C Lessard, J Hébert, D-C Roy, R Levine, L Busque.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18239619      PMCID： PMC4640460          DOI： 10.1038/leu.2008.6

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.

Authors:  Ross L Levine; Claude Belisle; Martha Wadleigh; David Zahrieh; Stephanie Lee; Pierre Chagnon; D Gary Gilliland; Lambert Busque
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

2.  Polycythemia vera is not initiated by JAK2V617F mutation.

Authors:  Roberto H Nussenzveig; Sabina I Swierczek; Jaroslav Jelinek; Amos Gaikwad; Enli Liu; Srdan Verstovsek; Jaroslav F Prchal; Josef T Prchal
Journal:  Exp Hematol       Date:  2007-01       Impact factor: 3.084

3.  JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.

Authors:  Elisa Rumi; Francesco Passamonti; Daniela Pietra; Matteo G Della Porta; Luca Arcaini; Sabrina Boggi; Chiara Elena; Emanuela Boveri; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola
Journal:  Cancer       Date:  2006-11-01       Impact factor: 6.860

4.  Non-leukemic autologous reconstitution after allogeneic bone marrow transplantation for Ph-positive chronic myelogenous leukemia: extended remission preceding eventual relapse.

Authors:  C G Brunstein; B A Hirsch; J S Miller; R C McGlennen; C M Verfaillie; P B McGlave; D J Weisdorf
Journal:  Bone Marrow Transplant       Date:  2000-12       Impact factor: 5.483

5.  Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

Authors:  Robert Kralovics; Soon-Siong Teo; Sai Li; Alexandre Theocharides; Andreas S Buser; Andre Tichelli; Radek C Skoda
Journal:  Blood       Date:  2006-05-04       Impact factor: 22.113

6.  Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.

Authors:  Christine Bellanné-Chantelot; Isabelle Chaumarel; Myriam Labopin; Florence Bellanger; Véronique Barbu; Claudia De Toma; François Delhommeau; Nicole Casadevall; William Vainchenker; Gilles Thomas; Albert Najman
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

7.  Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

Authors:  Alexandre Theocharides; Marjorie Boissinot; François Girodon; Richard Garand; Soon-Siong Teo; Eric Lippert; Pascaline Talmant; Andre Tichelli; Sylvie Hermouet; Radek C Skoda
Journal:  Blood       Date:  2007-03-15       Impact factor: 22.113

8.  Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

Authors:  Peter J Campbell; E Joanna Baxter; Philip A Beer; Linda M Scott; Anthony J Bench; Brian J P Huntly; Wendy N Erber; Rajko Kusec; Thomas Stauffer Larsen; Stéphane Giraudier; Marie-Caroline Le Bousse-Kerdilès; Martin Griesshammer; John T Reilly; Betty Y Cheung; Claire N Harrison; Anthony R Green
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113
  8 in total
  5 in total

1.  JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies.

Authors:  Andreas Kreft; Thomas Kindler; Erik Springer; Charles James Kirkpatrick
Journal:  Virchows Arch       Date:  2011-10-18       Impact factor: 4.064

Review 2.  Molecular classification of myeloproliferative neoplasms-pros and cons.

Authors:  Moosa Qureshi; Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 3.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08

Review 4.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.

Authors:  A Tefferi
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

5.  DLGAP1 directs megakaryocytic growth and differentiation in an MPL dependent manner in hematopoietic cells.

Authors:  Boguslaw A Kwiatkowski; Nicolas R Burwick; Robert E Richard
Journal:  Biomark Res       Date:  2019-07-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.